Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML.
Fiskus W, Mill CP, Bose P, Masarova L, Pemmaraju N, Dunbar A, Birdwell C, Davis JA, Das K, Hou H, Manshouri T, Jain A, Malovannaya A, Philip K, Alhamadani N, Matthews A, Lin K, Flores L, Loghavi S, DiNardo CD, Su X, Rampal RK, Bhalla KN.
Fiskus W, et al. Among authors: davis ja.
Blood. 2024 Nov 19:blood.2024026388. doi: 10.1182/blood.2024026388. Online ahead of print.
Blood. 2024.
PMID: 39561280